心通医疗－Ｂ(02160.HK) 发盈警，预计2024年度亏损介乎3,000万至6,000万人民币，较2023年度减少87%-94%。主要因集团的经导管主动脉瓣膜植入术产品VitaFlow及VitaFlow Liberty和AnchorMan左心耳封堵器系统及其导引系统在内地的商业化有序推进，植入量持续增长；VitaFlow Liberty经导管主动脉瓣膜及可回收输送系统获得CE标志，并已在海外17个国家/地区实现销售，来自海外的收入增长一倍以上；进一步开展降本控费，提升生产效率；及转回联营4C Medical前期计提的减值准备。(de/d)(港股报价延迟最少十五分钟。)
| 公布日期 | 派息事项 | 派息内容 |
|---|---|---|
| 2024/08/28 | 中期业绩 | 无派息 |
| 2024/03/27 | 末期业绩 | 无派息 |
| 2023/08/29 | 中期业绩 | 无派息 |
| 2023/03/29 | 末期业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.